Cloudbreak Pharma Inc. (CLOUDBREAK-B) has fully redeemed its investment in an offshore fund, receiving HK$48.00 million in proceeds and realizing a HK$0.88 million gain, equivalent to an annualised return of 2.53%. The board resolved to exit the position to rectify a previously disclosed deviation from the prescribed Use of Proceeds.

The redeemed vehicle is an exempted segregated portfolio company regulated by the Cayman Islands Monetary Authority, with assets under management exceeding US$100.00 million and more than 10 institutional investors. No single investor holds over 10% of the fund. Voting control rests with Ms. Saadeddine Hanane, who is deemed the ultimate beneficial owner. The company confirmed that the fund and all related parties are independent third parties to Cloudbreak Pharma.

By concluding the redemption, Cloudbreak Pharma aligns its capital deployment with the intended purposes outlined in its prospectus and removes the compliance overhang highlighted in the 30 March 2026 announcement.